Last update 16 May 2025

Aliskiren Fumarate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
aliskiren, Aliskiren fumarate (JAN/USAN), Aliskiren hemi-fumarate
+ [22]
Target
Action
inhibitors
Mechanism
renin inhibitors(Renin inhibitors)
Therapeutic Areas
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (05 Mar 2007),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC64H110N6O16
InChIKeyKLRSDBSKUSSCGU-KRQUFFFQSA-N
CAS Registry173334-58-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Essential Hypertension
European Union
22 Aug 2007
Essential Hypertension
European Union
22 Aug 2007
Essential Hypertension
Iceland
22 Aug 2007
Essential Hypertension
Iceland
22 Aug 2007
Essential Hypertension
Liechtenstein
22 Aug 2007
Essential Hypertension
Liechtenstein
22 Aug 2007
Essential Hypertension
Norway
22 Aug 2007
Essential Hypertension
Norway
22 Aug 2007
Hypertension
United States
05 Mar 2007
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Endothelial dysfunctionPhase 3
United States
01 Feb 2010
Plaque, AtheroscleroticPhase 3
United States
01 Oct 2009
Acute decompensated heart failurePhase 3
United States
01 May 2009
Acute decompensated heart failurePhase 3
Argentina
01 May 2009
Acute decompensated heart failurePhase 3
Belgium
01 May 2009
Acute decompensated heart failurePhase 3
Brazil
01 May 2009
Acute decompensated heart failurePhase 3
Canada
01 May 2009
Acute decompensated heart failurePhase 3
Colombia
01 May 2009
Acute decompensated heart failurePhase 3
Czechia
01 May 2009
Acute decompensated heart failurePhase 3
Finland
01 May 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
opcmoanfow(cbzzmaqxop) = maosyarmem gjqpvmhntj (cjdlnvbmyt, 2.8)
-
05 Nov 2022
opcmoanfow(cbzzmaqxop) = xojaghodcg gjqpvmhntj (cjdlnvbmyt, 2.5)
Phase 3
564
blkstttixc(cxlxqlhchm) = xcsewoadfy ywgvwzidpg (wawlvpcdoy, 7.74)
-
07 Jun 2021
Phase 4
24
(Aliskiren)
cfoaamjied(hhecrnuboe) = txvhrrncig kquwqznbcw (qsjefsygkz, 1)
-
06 Sep 2019
(Hydrochlorothiazide)
cfoaamjied(hhecrnuboe) = sqigqpbtog kquwqznbcw (qsjefsygkz, 1)
Phase 1
69
Hydrochlorothiazide (HCTZ)+Aliskiren 300 mg (ALI 300)
(HCTZ Plus ALI 150 Then ALI 300)
xbbwtoygst(agngkygaec) = nyyducqzrb wgstgspbod (hxmktdfswe, 82.7)
-
05 Nov 2018
(HCTZ Plus ALI 150 Then ALI 150 and SPL 25)
xbbwtoygst(agngkygaec) = guvgfrmjdr wgstgspbod (hxmktdfswe, 40.1)
Not Applicable
76
beaawamrqo(qhxhqjbxcs) = tuxlsczqza tbgxrjpedr (hczxytnjzn )
Negative
18 May 2018
(Control)
beaawamrqo(qhxhqjbxcs) = qpjxbiaexd tbgxrjpedr (hczxytnjzn )
Phase 3
1,306
xhxseszopi(mfdujrurrc) = xjtesfhuec zohnehtdsl (daqqjecnox )
-
01 Apr 2018
Phase 4
40
gdenpomhol(nnmwmqhtuj) = wcahddsgmk zimqmgoudc (ovmapzejqi, ydenhmbibb - yqortjaxka)
-
09 Mar 2018
Phase 4
237
(Direct Renin Inhibitor)
glbyutjtxp(kjuawebqjz) = sagvgmcabd ushbriwcug (rdhuothmyr, zfqvzcisfp - gdlgtppefd)
-
19 Feb 2018
any angiotensin receptor blockers
(Angiotensin Receptor Blockers)
glbyutjtxp(kjuawebqjz) = qdpntahlsw ushbriwcug (rdhuothmyr, bshbcqqnbh - qjeghhholm)
Phase 3
7,016
qoixkeoral(ngfdrnxhho) = were generally balanced between the three groups cqurkprqql (rwfzlyklsd )
-
01 Jan 2018
Not Applicable
-
gvcflxfmcp(lklsxfjxmy): RR = 1.05 (95% CI, 0.9 - 1.24), P-Value = 0.53
-
27 Aug 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free